Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and PK of CJ-15314 in Healthy Males
NCT04297865Phase 1Unknown
- Sponsor
- HK inno.N Corporation
- Start
- Feb 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CJ-15314 in rheumatoid arthritis (RA) (6 cohorts), sponsored by HK inno.N Corporation. Primary endpoints: Maximum Plasma Concentration up to 72 hours, Time to Maximum Plasma Concentration up to 72 hours and 13 more. Status: unknown.
02
Drugs
CJ-15314
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04297865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04297865.